Japanese Pharma Giant to acquire US Cancer Drug Startup Deciphera 

A major pharmaceutical company based in Tokyo has announced plans to purchase an American biotechnology startup specializing in oncology therapies. Ono Pharmaceutical revealed an agreement to acquire all outstanding shares of Deciphera Pharmaceuticals for approximately $2.4 billion USD. The boards of both firms unanimously approved the all-cash deal, which is expected to close this summer pending customary closing conditions.

Founded in 2003, Deciphera is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for cancer patients. The acquisition will allow Ono to strengthen its research and development portfolio in oncology. By obtaining Deciphera’s pipeline of innovative drug candidates and commercial infrastructure in the US and Europe, Ono aims to accelerate its efforts to develop new therapies for cancer.

The purchase represents a significant step for Ono to expand its global presence and capabilities in precision oncology. As a recognized leader in pharmaceutical research and healthcare in Japan, the acquisition positions Ono for further growth internationally through Deciphera’s clinical programs and commercial assets. Both companies believe the transaction will benefit cancer patients by enabling greater resources to be devoted to advancing promising new treatment options.